Novo's amycretin gets 22% weight loss in trial

[clayd]

Novo has a cagrisema successor, amycretin, that hits the GLP1 AND amylin receptors with a single molecule. Good results from phase 1b/2a trial of up to 22% loss. Shares up.10%

News Details

www.novonordisk.com

 

[penewbie]

22% in 36 weeks. That's reta level loss, and it hits the amylin receptor that reta doesn't. I suspect a lot of stacking in the future.

Come on vendors, what are you waiting for? A new drug with the possibility of price gouging before everyone else starts making it.

 

[clayd]

22% in 36 weeks. That's reta level loss, and it hits the amylin receptor that reta doesn't. I suspect a lot of stacking in the future.

Come on vendors, what are you waiting for? A new drug with the possibility of price gouging before everyone else starts making it.

This is where I'm at. C'mon folks you can do amycretin, MariTide, orgawhatever, eloralintide, people would snap it up